The current guidelines recommend that potassium iodide be given in the immediate preoperative period for patients with Graves’ disease who are undergoing thyroidectomy. Nonetheless, the evidence behind this recommendation is tenuous. The purpose of this study is to clarify the benefits of preoperative iodine administration from published comparative studies.
Data Sources
We searched PubMed, Embase, Cochrane, and CINAHL from 1980 to June 2018.
Review Methods
Studies were included that compared preoperative iodine administration and no premedication before thyroidectomy. For the meta-analysis, studies were pooled with the random-effects model.
Results
A total of 510 patients were divided into the iodine (n = 223) and control (n = 287) groups from 9 selected studies. Preoperative iodine administration was significantly associated with decreased thyroid vascularity and intraoperative blood loss. Significant heterogeneity was present among studies. We found no significant difference in thyroid volume or operative time. Furthermore, the meta-analysis showed no difference in the risk of postoperative complications, including vocal cord palsy, hypoparathyroidism/hypocalcemia, and hemorrhage or hematoma after thyroidectomy.
Conclusion
Preoperative iodine administration decreases thyroid vascularity and intraoperative blood loss. Nonetheless, it does not translate to more clinically meaningful differences in terms of operative time and postoperative complications.
De LeoSLeeSYBravermanLE.Hyperthyroidism. Lancet. 2016;388:906-918.
2.
Schussler-FiorenzaCMBrunsCMChenH.The surgical management of Graves’ disease. J Surg Res. 2006;133:207-214.
3.
BaezaAAguayoJBarriaMPinedaG.Rapid preoperative preparation in hyperthyroidism. Clin Endocrinol (Oxf). 1991;35:439-442.
4.
LeungAMBravermanLE.Consequences of excess iodine. Nat Rev Endocrinol. 2014;10:136-142.
5.
PlummerHS.Results of administering iodine to patients having exophthalmic goiter. JAMA. 1923;80:1955.
6.
BahnRSBurchHBCooperDSet al; American Thyroid Association; American Association of Clinical Endocrinologists. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21:593-646.
7.
RossDSBurchHBCooperDSet al. 2016American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26:1343-1421.
8.
ShinallMCJrBroomeJTBakerASolorzanoCC.Is potassium iodide solution necessary before total thyroidectomy for Graves disease?Ann Surg Oncol. 2013;20:2964-2967.
9.
HopeNKellyA.Pre-operative Lugol’s iodine treatment in the management of patients undergoing thyroidectomy for Graves’ disease: a review of the literature. Eur Thyroid J. 2017;6:20-25.
10.
MoherDShamseerLClarkeMet al; PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
11.
ChengSPLeeJJLiuTPet al. Quality of life after surgery or surveillance for asymptomatic primary hyperparathyroidism: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2015;94:e931.
12.
ChangYCLiuCLLiuTPYangPSChenMJChengSP.Effect of perioperative intravenous lidocaine infusion on acute and chronic pain after breast surgery: a meta-analysis of randomized controlled trials. Pain Pract. 2017;17:336-343.
13.
ChengSPLiuTPYangPSLeeKSLiuCL.Effect of perioperative dexamethasone on subjective voice quality after thyroidectomy: a meta-analysis and systematic review. Langenbecks Arch Surg. 2015;400:929-936.
14.
TsaiCCYangPSLiuCLWuCJHsuYCChengSP.Comparison of topical mupirocin and gentamicin in the prevention of peritoneal dialysis-related infections: a systematic review and meta-analysis. Am J Surg. 2018;215:179-185.
15.
WilkinTJGunnAAl MoussaMIslesTECrooksJSwanson BeckJ.The relationships between surgical histometry, outcome and pre-treatment in Graves’ disease. Acta Endocrinol (Copenh). 1981;98:43-49.
16.
WilsonRMcKillopJHThomsonJA.The effect of pre-operative potassium iodide therapy on antibody production. Acta Endocrinol (Copenh). 1990;123:531-534.
17.
CoylePJMitchellJE.Thyroidectomy: is Lugol’s iodine necessary?Ann R Coll Surg Engl. 1982;64:334-335.
18.
PedenNRBrowningMCFeelyJet al. The clinical and metabolic responses to early surgical treatment for hyperthyroid Graves’ disease: a comparison of three pre-operative treatment regimens. Q J Med. 1985;56:579-591.
19.
RandleRWBatesMFLongKLPittSCSchneiderDFSippelRS.Impact of potassium iodide on thyroidectomy for Graves’ disease: implications for safety and operative difficulty. Surgery. 2018;163:68-72.
20.
WhalenGSullivanMMarandaLQuinlanRLarkinA.Randomized trial of a short course of preoperative potassium iodide in patients undergoing thyroidectomy for Graves’ disease. Am J Surg. 2017;213:805-809.
21.
YilmazYKamerKEUreyenOSariEAcarTKarahalliO.The effect of preoperative Lugol’s iodine on intraoperative bleeding in patients with hyperthyroidism. Ann Med Surg (Lond). 2016;9:53-57.
22.
YabutaTItoYHirokawaMet al. Preoperative administration of excess iodide increases thyroid volume of patients with Graves’ disease. Endocr J. 2009;56:371-375.
23.
HassanIDanilaRAljabriHet al. Is rapid preparation for thyroidectomy in severe Graves’ disease beneficial? The relationship between clinical and immunohistochemical aspects. Endocrine. 2008;33:189-195.
24.
ErbilYOzlukYGirisMet al. Effect of lugol solution on thyroid gland blood flow and microvessel density in the patients with Graves’ disease. J Clin Endocrinol Metab. 2007;92:2182-2189.
25.
MarmonLAuFC.The preoperative use of iodine solution in thyrotoxic patients prepared with propranolol: is it necessary?Am Surg. 1989;55:629-631.
26.
KaurSParrJHRamsayIDHennebryTMJarvisKJLesterE.Effect of preoperative iodine in patients with Graves’ disease controlled with antithyroid drugs and thyroxine. Ann R Coll Surg Engl. 1988;70:123-127.
27.
ChangDCWheelerMHWoodcockJPet al. The effect of preoperative Lugol’s iodine on thyroid blood flow in patients with Graves’ hyperthyroidism. Surgery. 1987;102:1055-1061.
28.
HuangSMChowNHLeeHLWuTJ.The value of color flow Doppler ultrasonography of the superior thyroid artery in the surgical management of Graves disease. Arch Surg. 2003;138:146-151.
29.
MokVMOltmannSCChenHSippelRSSchneiderDF.Identifying predictors of a difficult thyroidectomy. J Surg Res. 2014;190:157-163.
30.
QuimbyAEWellsSTHearnMJavidniaHJohnson-ObasekiS.Is there a group of patients at greater risk for hematoma following thyroidectomy? A systematic review and meta-analysis. Laryngoscope. 2017;127:1483-1490.
31.
CalissendorffJFalhammarH.Lugol’s solution and other iodide preparations: perspectives and research directions in Graves’ disease. Endocrine. 2017;58:467-473.
32.
YamadaEYamazakiKTakanoKObaraTSatoK.Iodide inhibits vascular endothelial growth factor-A expression in cultured human thyroid follicles: a microarray search for effects of thyrotropin and iodide on angiogenesis factors. Thyroid. 2006;16:545-554.
33.
SuzukiKKimuraHWuHet al. Excess iodide decreases transcription of NIS and VEGF genes in rat FRTL-5 thyroid cells. Biochem Biophys Res Commun. 2010;393:286-290.
34.
YamazakiKTanigawaKSuzukiKet al. Iodide-induced chemokines and genes related to immunological function in cultured human thyroid follicles in the presence of thyrotropin. Thyroid. 2010;20:67-76.
35.
HuangSMLiaoWTLinCFSunHSChowNH.Effectiveness and mechanism of preoperative Lugol solution for reducing thyroid blood flow in patients with euthyroid Graves’ disease. World J Surg. 2016;40:505-509.
36.
YamanouchiKMinamiSHayashidaNSakimuraCKurokiTEguchiS.Predictive factors for intraoperative excessive bleeding in Graves’ disease. Asian J Surg. 2015;38:1-5.
37.
ShinallMCJrBroomeJTNookalaRet al. Total thyroidectomy for Graves’ disease: compliance with American Thyroid Association guidelines may not always be necessary. Surgery. 2013;154:1009-1015.
38.
SantoshUPPrashanthKBKaranamL.Preoperative preparation with Lugol’s iodine in thyroidectomy of euthyroid patients—is it really mandatory? An otorhinolaryngologist’s view. J Clin Diagn Res. 2014;8:KC01-KC02.
39.
MercierFBonalMFangetFet al. Does surgery without Lugol’s solution pretreatment for Graves’ disease increase surgical morbidity?World J Surg. 2018;42:2123-2126.
40.
WartofskyLRansilBJIngbarSH.Inhibition by iodine of the release of thyroxine from the thyroid glands of patients with thyrotoxicosis. J Clin Invest. 1970;49:78-86.
41.
MarigoldJHMorganAKEarleDJYoungAECroftDN.Lugol’s iodine: its effect on thyroid blood flow in patients with thyrotoxicosis. Br J Surg. 1985;72:45-47.
42.
LangeMJ.Thyroidectomy: is Lugol’s iodine necessary?Ann R Coll Surg Engl. 1983;65:63-64.
43.
SchneiderDFMazehHOltmannSCChenHSippelRS.Novel thyroidectomy difficulty scale correlates with operative times. World J Surg. 2014;38:1984-1989.
44.
CalissendorffJFalhammarH.Rescue pre-operative treatment with Lugol’s solution in uncontrolled Graves’ disease. Endocr Connect. 2017;6:200-205.
45.
ErbilYGirisMSalmasliogluAet al. The effect of anti-thyroid drug treatment duration on thyroid gland microvessel density and intraoperative blood loss in patients with Graves’ disease. Surgery. 2008;143:216-225.
